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ABSTRACT 
Introduction: Diabetes is difficult to manage 
and treatment involves significant lifestyle 
adjustments. Unlike the traditional method of 
insulin administration via the vial and syringe 
method, insulin pens might be perceived as less 
cumbersome and have potential to significantly 
increase patient adherence. Methods: Using 
“real world” data, we examined the differences 
in adherence and costs between diabetic 
patients using 
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an insulin FlexPen® (Novo Nordisk Inc, 
Princeton, NJ, USA) and those using traditional 
vial and syringe administration. Using a 
retrospective analysis of health insurance 
claims data between the years 2003 and 2008, 
we examined patients in the FlexPen cohort and 
analog vial cohort. Propensity score matching 
was used to match these cohorts (n=532 in each) 
according to baseline characteristics. Results: 
Adjusted mean medication possession ratio 
when switched to FlexPen improved by 22 
percentage points versus 13 percentage points 
when continuing to use vials (P=0.001). 
Diabetes- related healthcare costs when 
switched to FlexPen versus continuing on to 
use vials ($3970 vs. $4838, respectively, 
P=0.9368) and total healthcare costs ($13,214 vs. 
$13,212, respectively, P=0.9473) were not 
statistically different. Conclusion: Without 
significant addition to the cost, insulin 
administration with FlexPen is associated with 
an improved adherence among patients who 
switched from vial-based insulin 
administration. 
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INTRODUCTION 
Adherence to therapy is a major impact 
factor with respect to treatment success. For 
treatments such as those for type 2 diabetes, 
adherence to therapy can be perceived as 
particularly challenging as it is a lifelong chronic 
disease and patients may not feel the immediate 
consequences when skipping doses. Poor 
adherence to diabetes therapy, however, may 
have serious long-term and detrimental effects 
as patients are not in adequate glycemic control, 
which negatively affects risk of diabetes-related 
complications.1 Landmark studies, such as the 
United Kingdom Prospective Diabetes Study 
(UKPDS), have shown that glycemic control as 
measured by glycated hemoglobin (HbA1c)  is 
a very important risk factor of complications, 
including blindness,  amputations and 
cardiovascular disease.2 
Type 2 diabetes imposes a significant burden 
on the US healthcare system. The American 
Diabetes Association estimates that 17.5 million 
Americans suffer from diabetes and that the total 
cost of diabetes in 2007 was $174 billion, with 
$116 billion direct costs to healthcare.3 Type 2 
diabetes is considered to make up 90%-95% of 
all diabetes cases.4 Most of the burden and costs 
of diabetes originate from complications and 
treatment of complications (eg, >50% of costs are 
incurred in a hospital inpatient care setting).3 
Thus, improvements in treatments and 
better adherence to treatments could benefit 
patients as well as healthcare plans and payers. 
Insulin therapy in particular can be of particular 
concern with respect to adherence because it is 
associated with hypoglycemic events, and due to 
the fact it is an injectable therapy, which might 
be perceived as inconvenient and/or difficult 
to administer by both patients and prescribers. 
Initiating and switching insulin therapy can be 
complicated for patients as well as prescribers, 
as insulin therapy, whether used in vials or 
pens, demands extensive patient education and 
training. Treatments associated with discomfort 
such as injections, or risk of adverse events such 
as hypoglycemia, might keep some patients 
from faithfully following treatment guidelines, 
thereby reducing adherence.5 
Poor adherence to long-term therapies 
compromises the effectiveness of treatment, 
making this a critical issue in population health 
from the perspective of both quality of life and 
health economics. It has been shown that poor 
adherence attenuates optimum clinical benefit.6 
Therefore, medical innovations aimed at 
improving adherence might provide significant 
positive return investments through prevention 
of adverse health outcomes. Ease of use coupled 
with safety and dosing accuracy are ways to 
potentially improve adherence to therapy.7,8 
Insulin delivery by vial and syringe 
administration could be perceived as less 
convenient and less flexible for patients than 
pen-administered insulin for several reasons. The 
vial and syringe method requires complex dosing 
preparations and a longer training time, can be 
difficult to transport, uncomfortable for patients 
to self-inject, and might be associated with social 
stigma for some patients. Insulin delivery pens are 
generally easier to manage for patients and easier 
to teach how to use by healthcare professionals. 
Furthermore, pens are more discreet, easier to 
transport, provide better dosing accuracy, and feel 
less like a true injection, with less pain than the 
vial and syringe method.9 
The present study was initiated, with the 
intention to analyze the impact on patient 
adherence, hypoglycemic events and treatment 
costs when switching from an insulin vial 
regimen to a FlexPen® (Novo Nordisk Inc, 
Princeton, NJ, USA) insulin pen regimen. 
A study published in 2006 also set out to 
analyze the impact on adherence, hypoglycemia 
 
 
 
 
and costs when switching from vial to 
FlexPen.10 In this study, it was reported that 
switching to FlexPen was indeed associated 
with improvements in adherence, which was 
accompanied by reductions in hypoglycemia 
as well as reductions in costs. The present study 
was conducted to analyze how adherence to 
therapy, insulin consumption, healthcare costs, 
and incidence of hypoglycemic events changed 
when patients were switched from vial therapy to 
FlexPen compared to a matched control cohort 
that did not switch but continued vial therapy. 
 
MATERIALS AND METHODS 
Data Sources and Study  Population 
 
Health Insurance Portabi l i ty  and 
Accountability Act (HIPAA)-compliant pharmacy 
and medical administrative claims data from a 
proprietary US health plan database was used 
for this retrospective and longitudinal study. For 
2008, data relating to approximately 14 million 
individuals is available. This data source is well 
validated, and represents one of the largest 
health plans in the US. These data were chosen 
because of their high validity and because they 
cover large numbers of patients across all parts 
of the US (see geographical split in Table 1). 
The primary endpoint of the study was 
adherence as measured by adjusted medication 
possession ratio (MPR; see below for details). 
Secondary endpoints were insulin consumption, 
hypoglycemic events and healthcare costs. 
Data were collected between January 1, 
2003 and March 31, 2008. The database’s study 
population included patients continuously 
enrolled in a commercial or Medicare health 
plan for at least 1 year. Patients had to have at 
least two insulin prescription fills during the 
pre-index period where at least one fill occurred 
during 1-6 month(s) before the index and at 
 
Table 1. Baseline characteristics of the cohorts. 
 
 FlexPen (n=532) Vial (n=532) P value 
Age, years (mean±SD) 47.18±14.9 47.61±15.3 0.6730 
Age group, n (%):    
0-17 28 (5.26) 18 (3.38) 0.1048 
18-34 71 (13.35) 92 (17.29) 0.0665 
35-44 112 (21.05) 92 (17.29) 0.1116 
45-54 128 (24.06) 140 (26.32) 0.4076 
55-64 151 (28.38) 128 (24.06) 0.0943 
65-74 32 (6.02) 47 (8.83) 0.0750 
75+ 10 (1.88) 15 (2.82) 0.3173 
Gender, n (%):    
Male 307 (57.71) 315 (59.21) 0.6184 
Female 225 (42.29) 217 (40.79) 0.6184 
Geographic region, n (%):    
Northeast 52 (9.77) 52 (9.77) 1.0000 
North Central 170 (31.95) 185 (34.77) 0.3063 
South 246 (46.24) 240 (45.11) 0.7021 
West 64 (12.03) 55 (10.34) 0.3558 
Unknown 0 (0.00 ) 0 (0.00) 1.0000 
 
 
 
Patients with diabetes with >2 years 
enrollment in commercial/Medicare 
health plan 
n=148,450 
Patients meeting study criteria 
n=23,529 
Patients on human insulin 
n=11,164 
FlexPen cohort, matched 
n=532 
Analog vial cohort, matched 
n=532 
 
least one fill during the 7-12 months before 
the index. 
Patients were excluded from the analysis: 
(1) if they switched to another insulin than the 
index insulin or to another pen than FlexPen 
during the follow-up period; (2) if they had a 
fill for an insulin pen device, an insulin pump, 
or inhaled insulin in the pre- index period; or 
(3) if they had a diagnosis of gestational 
diabetes during the pre- or post- index period. 
Patients were divided based on the two 
cohorts: FlexPen cohort and analog vial cohorts. 
We applied one-to-one matching to compare 
the outcomes of these cohorts. In Figure 1, a 
breakdown of the patient cohorts is shown. 
 
Statistical Analysis 
 
Baseline characteristics were compared 
between the patient cohorts and descriptive 
statistics were calculated as mean (±standard 
deviation) and percentages. Differences between 
the cohorts were analyzed using the t test, Mann- 
Whitney U tests and chi-square test. Propensity 
score matching was applied to compare the risk- 
adjusted outcomes. 
Propensity score matching is a technique 
that aims at adjusting for selection bias in 
nonexperimental, nonrandomized, and 
retrospective studies like the present one. By 
using propensity score matching, each patient in 
the FlexPen cohorts was “mirrored” by a patient 
with similar predefined characteristics in the 
cohorts not switching to FlexPen. The following 
characteristics were used to match: index year, 
diabetes type, age, age2, gender, Charlson 
Comorbidity Index (CCI), CCI2, geographic 
region, plan type, insulin consumption during 
baseline period, and commercial/Medicare. 
Logistic regression was used to estimate 
propensity scores. Several interaction variables 
were attempted but they were not significant. 
Estimation power  of  the  logistic  model 
is determined with C statistics. We used 
mahalanobis, kernel, one-to-one, and radius 
 
Figure 1. Flow chart of patients in the study. 
 
 
 
 
 
 
 
 
Analog vial cohort, unmatched 
n=11,129 
FlexPen cohort, unmatched 
n=1236 
 
 
 
 
matching techniques, and by following the 
guidelines set forth by Baser, determined that 
one-to-one matching created the best balance 
between the groups.11 To eliminate further 
differences between the groups after propensity 
score matching, regression analysis followed over 
the matched sample.12 Statistical analyses were 
performed using SAS v9.2 (SAS Institute, Cary, 
NC, USA) and STATA v10 (Stata Corp, College 
Station, TX, USA). 
 
Adherence Measure 
 
In this study, adherence to insulin therapy was 
measured among persistent patients (ie, patients 
who are not “dropping off” their insulin). Thus, 
adherence is a measure of how closely patients 
follow their medication regimen and not whether 
they remain on therapy. Traditionally, adherence 
is measured as the MPR, which is the total days’ 
supply of all prescriptions in the analysis period 
as registered by the pharmacy when the insulin 
prescription is filled, divided by number of days 
in the analysis period (ie, 365). Hence, unless a 
patient takes too much medication, MPR will be 
a number between 0 and 1, where 1 corresponds 
to the scenario where a patient adheres 100%  
to therapy. 
However, challenges exist when measuring 
adherence in a multidose treatment regimen 
such as insulin, as patients use different daily 
dosing dependent on, for example, body weight 
different, which is the case with insulin in a vial 
versus insulin in a FlexPen. Vials are sold in packs 
of 1000 units while the FlexPen comes in packs 
of 1500 units, without any noticeable difference 
in days’ supply, as indicated in Figure 2. 
To make adherence comparisons between the 
vials and the FlexPen feasible, it is necessary to 
adjust the MPR to account for the difference in 
package size. This adjusted MPR is calculated by 
using data based upon the actual gap between 
the days’ supply and the days to next refill for 
FlexPen and vials. Thus, the adjusted MPR for 
vials is calculated by multiplying the traditional 
MPR by (average days between prescription refills 
for patients using vials/average days’ supply for 
patients using vials). Likewise, the adjusted MPR 
for the FlexPen is calculated by multiplying the 
MPR by (average days between prescription 
refills for patients using FlexPen/average days’ 
supply for patients using FlexPen). In Figure 2, 
the discrepancy between days’ supply and the 
actual number of days to the next refill in the 
two cohorts is shown. 
As shown in Figure 2 the average days’ 
supply and days between refills for vial patients 
are reasonably alike, but for FlexPen users 
the value for average days between refills is 
 
Figure 2. Distribution of days supply of vials and FlexPen. 
Mean (including lower and upper 95% confidence 
intervals) days supplied and days between refills for 
FlexPen and vial users. 
and progression of diabetes. Despite this fact, 
almost all prescriptions are dispensed with a 
30-day supply documented by the pharmacy 
even if the patient has more insulin than ordered 
by the doctor after the 30-day period. Hence, 
patients might appear to be nonadherent as 
measured by MPR, even though they are in fact 
adherent to the instructions from their doctors. 
Analog vial days’ 
supply 
Analog vial days 
between refılls 
FlexPen days’ 
supply 
FlexPen days 
between refılls 
32.94 
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Furthermore, it can be a problem to compare the 
MPRs between treatments when package sizes are 
0 10 20 30 40 50 60 
Days 
 
 
 
 
substantially longer than average days’ supply. 
Hence, it is necessary to adjust the MPR as 
described above. 
 
Insulin Consumption 
 
Insulin daily average consumption (DACON), 
measured in insulin units, was computed 
from all prescription insulin fills based on the 
cohort. The total number of units dispensed 
was calculated as total milliliters dispensed for 
all prescriptions in the follow-up period (except 
the last fill in both the baseline and follow-up 
period) multiplied by 100, since there  are 
100 insulin units/mL. The total number of units 
dispensed was then divided by the number of 
days between index date and the date of last 
fill to calculate the average number of units of 
insulin per day. 
 
Safety and Effectiveness 
 
Only the hypoglycemic episodes obtained from 
the claims database that resulted in contact with 
healthcare professionals and were correctly coded 
with International Classification of Diseases, 
Ninth Revision: Clinical Modification (ICD-9-CM) 
codes were registered and used in the analysis. In 
particular, we looked at hypoglycemic coma (ICD- 
9-CM: 251.0), other specified hypoglycemia (ICD- 
9-CM: 251.1), and unspecified hypoglycemia 
(ICD-9-CM: 251.2). Also included are the claims 
with ICD-9-CM code 250.8 (diabetes with 
other specified manifestations). The number of 
hypoglycemic episodes was compared pre- and 
post-index date. 
Treatment effectiveness, preferably measured 
by changes in HbA1c was not analyzed as this 
was not feasible. Even though laboratory test 
results, such as HbA1c, are available for a subset 
of the data source used, there was not enough 
data available to keep an adequate number of 
patients with HbA1c values in both the pre- and 
post-index periods in the study. 
 
Healthcare Costs 
 
Costs of treatment and healthcare costs in 
general were compared between the cohorts in 
the 12 months before and after the index date, 
ie, the first FlexPen prescription. Costs were 
calculated using actual patient claims and, thus, 
represent the true reflection of healthcare use in 
the matched cohorts. 
 
 
Table 2. Insulin consumption and medication possession ratio. 
 
 Vial to FlexPen Analog vials  
(mean±SD) (mean±SD) P value 
12-month pre-index period    
MPR 0.52±0.27 0.52±0.24 0.7432 
DACON 42.13±58.34 42.64±26.82 0.0565 
12-month post-index period    
MPR* 0.55±0.31 0.60±0.30 0.0082 
DACON 46.27±40.13 45.11±27.51 0.9641 
Pre-index vial to FlexPen data are from patients who were using vial and syringe during the pre-index period, after which they 
switched to Flexpen. Their pre-index data reflect their vial and syringe baseline data. 
*FlexPen post-index MPR is based on a pack size with 50% more insulin and with no noticeable difference in prescription 
days’ supply (as seen in Figure 3). 
DACON=insulin daily average consumption; MPR=medication possession ratio. 
 
 
 
Pre-
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RESULTS 
Baseline characteristics are summarized for 
the two cohorts of each database in Table 1. Since 
the FlexPen and vial cohorts were matched, the 
cohorts are reasonably alike and there were no 
statistical differences between the characteristics 
of the cohorts. 
Daily consumption of insulin units and 
adherence to therapy pre- and post-index date 
are shown in Table 2.  FlexPen users tended  
to increase their insulin usage more than the 
control group, ie, the patients continuing the 
vial/syringe therapy. The increase in dose was 
statistically significant (P=0.0299). An increase 
in consumption might be an indication of 
improved adherence, as better adherence within 
the same dosing regimen will lead to observed 
higher consumption because of a reduction of 
skipped/missed doses. 
MPR improved between pre- and post-index 
for both cohorts. It is important to emphasize 
that MPR would be expected to decrease in 
the FlexPen cohorts without the days to next 
refill adjustment described earlier, because the 
pack in which it is sold contains 50% more 
units, and prescription days’ supply does not 
differ between vials and FlexPen, as shown in 
Figure 2. 
The adjusted MPR, controlling for the 
difference in pack size as well as patient 
baseline characteristics, showed that patients 
switching to FlexPen markedly improved 
adherence compared to the control group. As 
can be seen in Table 3, the patient level and 
adjusted mean MPR when switched to FlexPen 
improved by 0.22 versus 0.13 when continuing 
to use vials (P=0.001). 
Hypoglycemic events are shown in Figure 3. 
The numbers of hypoglycemic events in both 
pre- and post-index periods were relatively small, 
and no statistical differences could be detected. 
The cost of diabetes treatment and other 
healthcare costs are shown in Table 4. It can be 
seen that despite higher prescription costs in 
the FlexPen cohort, most likely due to higher 
acquisition costs of FlexPen versus vials, diabetes- 
related healthcare costs and total healthcare 
cost were not statistically different in the post- 
index period. 
 
Figure 3. Hypoglycemic events pre- and post-index. 
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Table 3. Change in adjusted adherence.  
 Vial to FlexPen 
(mean±SD) 
Analog vials 
(mean±SD) 
 
P value 
Change    
Adjusted MPR 0.22±0.01 0.13±0.36 0.0011 
DACON 3.27±0.85 2.18±0.65 0.001 
Change is defined as the difference on a patient level from the pre-index period and the post-index period (post-index value 
minus pre-index value). Adjusted change in MPR is controlled for difference in pack sizes as well as baseline differences in 
demographic and clinical factors (see Materials and Methods section). 
DACON=insulin daily average consumption; MPR=medication possession ratio. 
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Table 4. Costs of healthcare usage pre- and post-index. 
 
 Vial to FlexPen Analog vials  
 (mean±SD) (mean±SD) P value 
12-month pre-index period    
Total healthcare costs 13,983±31,596 11,977±20,198 0.8238 
Prescription costs 4328±5428 4582±4565 0.0455 
All medical costs 9655±30,432 7396±18,250 0.4545 
Diabetes-related medical costs 5241±19,009 3868±12,876 0.0107 
12-month post-index period    
Total healthcare costs 13,214±23,917 13,212±26,570 0.9473 
Prescription costs 5414± 7330 4790 ±4577 0.0802 
All medical costs 7800±22,282 8421±24,509 0.2789 
Diabetes-related medical costs 3970±12,851 4838±18,221 0.9368 
Pre-index vial to FlexPen data are from patients who were using vial and syringe during the pre-index period, after which they 
switched to FlexPen. Their pre-index data reflects their vial and syringe baseline data. 
 
DISCUSSION 
The data analyzed as part of this study, based 
on healthcare claims, suggest that switching 
from insulin administration with vial and 
syringe to FlexPen administration is associated 
with improvement in adherence, when 
measured as adjusted MPR, and increased insulin 
consumption. Across both cohorts, insulin 
consumption increased from the pre- and post- 
index periods. 
This is not surprising, as most patients 
will need more insulin over time to maintain 
glycemic control. It is important to remember 
that only patients who persisted with therapy 
were included, and therefore all patients 
probably tolerated treatment and benefited 
from it, which could be the reason for these dose 
increases. Any improvement of adherence is 
desirable, as treatment effects are dependent on 
patient adherence and, thus, impact the chance 
of treatment success.13 
As stated in the Materials and Methods 
section, MPR is difficult to interpret when 
dealing with multidose regimens such as 
insulin, and therefore it is not sensible to make 
 
conclusions based on the absolute value of the 
MPR (eg, that a patient with an MPR of 0.8 is 
more adherent to therapy than a patient with 
an MPR of 0.7). This does not mean, however, 
that comparisons of the changes in average MPR 
cannot be made, although they need be adjusted 
for the difference in pack sizes between FlexPen 
and vials. Even if interpersonal comparisons 
are problematic, intrapersonal comparisons, as 
undertaken in this study, are both reasonable 
and relevant. 
The speculated and potential benefits of pen 
therapy, as provided by (among others) the 
FlexPen, include ease of administration and 
other convenience parameters. It is possible that 
these convenience aspects may contribute to 
the observed improved adherence in this study 
when patients are switched to FlexPen from vial 
therapy. FlexPen, and insulin pens in general, 
are in most cases priced higher on a unit-to-unit 
basis compared to insulin in vials. 
This is also reflected in the results of this 
study, which shows that prescription costs, 
which were statistically significantly higher 
in the pre-index period, increase even though 
these are not statistically different in the post- 
 
 
 
 
index period. Pre-index diabetes-related medical 
costs were statistically significantly higher 
among patients that switched to FlexPen, but 
no statistical difference was found in the post- 
index period. Also, overall healthcare costs did 
not significantly differ between patients who 
switched to FlexPen and patients who continued 
using vials (the matched control group). 
Whether any impact of improved adherence 
can actually be seen in  the  short-term, which 
is the scope of the present analysis, is doubtful. 
Hence, it is probably not realistic to expect any 
major savings in medical service usage arising 
from improved adherence over the 12-month 
period applied here. 
Insulin analogs have been shown in 
randomized clinical trials to be associated with 
fewer hypoglycemic events compared to human 
insulins.14,15 It appears from the present study, 
however nonsignificant, that the patients 
switched from vial and syringe to FlexPen had 
a higher risk of hypoglycemic events before 
switching to FlexPen, and lower risk after the 
switch; however, this was not statistically 
significant either. Using claims databases to 
analyze the incidence and full economic burden 
of hypoglycemic events provides unique 
challenges. In order to be measured in claims 
data, the hypoglycemic event would require 
contact with a healthcare professional. Secondly, 
the event would have to be documented on a 
medical claim, using the appropriate ICD-9-CM 
diagnostic code. Obviously, only the most serious 
hypoglycemic event cases result in contacts 
with healthcare professionals and therefore the 
incidence seen in analyses like this one are much 
lower than for example, incidences in clinical 
trials or survey data. This under-reporting 
means that even though there appears to be a 
difference between the cohorts, the numbers are 
too small to show any statistical significance. In 
general, the analyzed data do not suggest any 
particular pattern with respect to hypoglycemic 
events before and after switching to the FlexPen, 
other than maybe that patients suffered from 
more events before they switched compared to 
patients who continued with vial therapy and 
fewer events after index. This was, however, not 
a statistically significant finding. 
As previously mentioned, a study published 
in 2006 also set out to investigate the association 
between FlexPen use and adherence, costs and 
hypoglycemic events.10 However, the results of 
the present study cannot be directly compared 
with the aforementioned previous research 
since the methods are somewhat different. Even 
though both studies are pre- and post-index 
comparisons, the most noticeable difference is 
that the present study is a case-control analysis 
where patients switching to the FlexPen are 
compared to a matched cohort of patients. The 
Lee et al.10 study reported improved adherence, 
lower incidence of hypoglycemic events, 
and a reduction in overall healthcare costs 
when patients switched from vial to FlexPen 
administration. In another study among 
Medicaid-enrolled patients, initiation of insulin 
with pens was associated with less healthcare 
usage compared to patients initiated with vial 
and syringe.16 The data source analyzed in 
the present study confirms improvement of 
adherence when comparing to a matched cohort 
of vial users. The results show that adherence 
among persistent patients improves despite the 
administration device (ie, adherence improves 
in both cohorts). However, adherence improves 
significantly more among patients who switched 
to FlexPen administration. With respect to 
hypoglycemic events, the incidence numbers 
found in this study were very small and hence it 
was not possible to draw any conclusions on this 
topic. Regarding healthcare costs, which were 
shown to be reduced in the Lee et al. study, there 
is nothing in the present study that suggests any 
 
 
 
 
difference in healthcare usage costs between 
FlexPen and vials users. 
Several limitations of retrospective database 
analyses, and claims data in particular, 
should be noted. First and foremost, this is 
nonrandomized data and, consequently, there is 
potential selection bias in the data. This study, 
however, adjusts for this by using the matched 
cohort case-control approach and by adjusting 
adherence for baseline characteristics, but this 
does not rule out selection bias completely as 
there is no knowledge of the exact reason why 
patients switched insulin administration vehicle. 
Another important caveat is the calculation 
and interpretation of the MPR. As stated above, 
interpretations of absolute values of MPR must 
be made with extreme caution, as prescription 
days’ supply does not necessarily reflect the 
expected time period that it is intended to fill. 
Furthermore, insulin usage as captured by claims 
data can be affected by, for example, wastage, 
and this cannot be adjusted for. However, there 
is no reason to suspect that the cohorts should 
be different in these matters, and emphasis of 
MPR should be put on the relative and pack size- 
adjusted differences. 
 
CONCLUSIONS 
This study has shown that insulin 
administration with FlexPen is associated with 
an improved adherence among patients who 
switch from vial-based insulin administration. 
This is based on an analysis of a data source 
using case-control analytics between cohorts that 
were matched for propensity score to control for 
selection bias. 
This study also investigated the impact on 
incidence of hypoglycemic events as well as 
healthcare costs when patients switched to the 
FlexPen. However, hypoglycemic events as 
reported in claims databases are too sparse 
to make any firm and statistically significant 
conclusions, but a trend towards improvements 
when patients were switched to the FlexPen was 
observed. Even though the FlexPen is associated 
with higher acquisition costs, this study showed 
that there was no difference with respect to 
overall healthcare costs. 
 
ACKNOWLEDGMENTS 
Funding/support was from Novo Nordisk Inc. 
OB acted as guarantor author. MA, JB, and TDL 
are employees of Novo Nordisk. 
 
REFERENCES 
 
1. Gonder-Frederick L, Cox D, Ritterband L. Diabetes 
and behavioral medicine: the second decade. J 
Consult Clin Psychol. 2002;70:611-625. 
 
2. Clarke P, Gray A, Briggs A, et al. A model to estimate 
the lifetime health  outcomes  of  patients  with 
type 2 diabetes: the United Kingdom Prospective 
Diabetes Study (UKPDS) Outcomes Model (UKPDS 
no. 68). Diabetologia. 2004;47:1747-1759. 
 
3. American   Diabetes   Association.    Economic 
costs of diabetes in the U.S. in 2007.  Diabetes  
Care. 2008;31:596-615. 
 
4. Wild S, Roglic G, Green A, Sicree R, King H.  
Global prevalence of diabetes estimates for the 
year 2000 and  projections  for  2030.  Diabetes  
Care. 2004;27:1047-1053. 
 
5. Burge M, Gamache L, Pai H, Segal A. Hypoglycemia 
and self-care in elderly patients with diabetes 
mellitus. In: Munshi MN, Lipsitz LA,  eds.  
Geriatric Diabetes. New York, USA: Informa 
Healthcare; 2007:331-356. 
 
6. Burkhart P, Dunbar-Jacob J. Adherence research in 
the pediatric and adolescent populations: a decade 
in review. In: Hayman LL, Mahon MM, Turner JR. 
Chronic Illness in Children: An Evidence-based 
Approach. New York, USA: Springer; 2002:199-229. 
 
7. Hirsch   I.   Insulin    analogues.    N    Engl    J    
Med. 2005;352:174-183. 
 
8. Oiknine R,  Bernbaum  M,  Mooradian  A.  A  
critical appraisal of the role of insulin analogues 
 
 
 
 
 
 
 
9. 
 
 
 
10. 
 
 
 
 
11. 
 
 
12. 
in  the  management   of   diabetes   mellitus. 
Drugs. 2005;65:325. 
 
Molife C, Lee L, Shi L, Sawhney M, Lenox S. 
Assessment of patient-reported outcomes of insulin 
pen devices versus conventional vial and syringe. 
Diabetes Technol Ther. 2009;11:529-538. 
 
Lee W, Balu S, Cobden D, Joshi A, Pashos C. 
Medication adherence and the associated health- 
economic impact among patients with type 2 
diabetes mellitus converting to insulin  pen 
therapy: an analysis of third-party managed care 
claims data. Clin Ther. 2006;28:1712-1725. 
 
Baser O. Too much ado about propensity score 
models? Comparing methods of propensity score 
matching. Value Health. 2006;9:377-385. 
 
Stukel  TA,  Fisher  ES,  Wennberg   DE,   Alter   
DA, Gottlieb DJ, Vermeulen MJ. Analysis of 
observational studies in the presence of treatment 
selection bias: effects of invasive cardiac 
 
 
 
13. 
 
14. 
 
 
15. 
 
 
 
 
16. 
management on AMI survival using propensity 
score and instrumental variable methods. J Am 
Med Assoc. 2007;297:278. 
 
Osterberg L, Blaschke T. Adherence to medication. 
N Engl J Med. 2005;353:487-497. 
 
Brixner D, McAdam-Marx C. Cost-effectiveness of 
insulin analogs. Am J Manag Care. 2008;14:766- 
775. 
 
Brunton S. Safety and effectiveness of 
modern insulin therapy. Current issues in the 
management of type 2 diabetes. ConsultantLive, 
July 2009. Available at: imaging.ubmmedica. 
com/consultantlive/supplements/0907Con_ 
DiabetesSup_HR.pdf. Accessed: March 8, 2010. 
 
Pawaskar MD, Camacho FT, Anderson RT, Cobden 
D, Joshi AV, Balkrishnan R. Healthcare costs and 
medication adherence associated with initiation of 
insulin pen therapy in Medicaid-enrolled patients 
with type 2 diabetes: a retrospective database 
analysis. Clin Ther. 2007;29:1294-1305. 
